Clinical relevance of biologic factors in male breast cancer

Breast Cancer Research and Treatment

Volumn 68, Issue 3, 2001, Pages 249-260

  Meijer van Gelder, Marion E ^a,b   Look, Maxime P ^a   Vries, Joan Bolt De ^a   Peters, Harry A ^a   Klijn, Jan G M ^a   Foekens, John A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Biologic factors; Breast cancer; Female; Male; Prognosis

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METABOLISM; MORTALITY; NETHERLANDS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGE; NETHERLANDS; PROGNOSIS; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035435082     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012221921416     Document Type: Article

References (55)

1. van Geel AN, van Slooten EA, Mavrunac M, Hart AA: A retrospective study of male breast cancer in Holland. Br J Surg 72: 724-727, 1985
2. Ewertz M, Holmberg L, Karjalainen S, Tretli S, Adami HO: Incidence of male breast cancer in Scandinavia, 1943-1982. Int J Cancer 43: 27-31, 1989
3. La Vecchia C, Levi F, Lucchini F: Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 51: 62-66, 1992
4. Donegan WL, Redlich PN: Breast cancer in men. Surg Clin North Am 76: 343-363, 1996
5. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, Osborne MP, McKinnon WM: Current management of male breast cancer. A review of 104 cases. Ann Surg 215: 451-457; discussion 457-459, 1992
6. McLachlan SA, Erlichman C, Liu FF, Miller N, Pintilie M: Male breast cancer: an 11 year review of 66 patients. Breast Cancer Res Treat 40: 225-230, 1996
7. Donegan WL, Redlich PN, Lang PJ, Gall MT: Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83: 498-509, 1998
8. Ciatto S, Iossa A, Bonardi R, Pacini P: Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Ilaly. Tumori 76: 555-558, 1990
9. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS: Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77: 490-498, 1996
10. Adami HO, Hakulinen T, Ewertz M, Tretli S, Holmberg L, Karjalainen S: The survival pattern in male breast cancer. An analysis of 1429 patients from the Nordic countries. Cancer 64: 1177-1182, 1989
11. Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, Fruhwirth H, Dunser M, Beller S, Haid A, Tüchler H: Male breast cancer: Austrian experience. World J Surg 19: 687-692; discussion 692-693, 1995
12. Weber-Chappuis K, Bieri-Burger S, Hurlimann J: Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32A: 1686-1692, 1996
13. Borgen PI, Senie RT, McKinnon WM, Rosen PP: Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 4: 385-388, 1997
14. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blarney RW, Robertson JF: A comparison outcome of male breast cancer with female breast cancer. Am J Surg 173: 185-188, 1997
15. Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F, Grassi M: Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 7: 930-935, 1994
16. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW: Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 188: 60-65, 1978
17. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997
18. May FE, Westley BR: Trefoil proteins: their role in normal and malignant cells. J Pathol 183: 4-7, 1997
19. Look MP, Foekens JA: Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 107: 150-159, 1999
20. Westley BR, May FE: Prognostic value of cathepsin D in breast cancer. Br J Cancer 79: 189-190, 1999
21. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995
22. Klijn JG, Berns EM, Foekens JA: Prognostic and predictive factors in breast cancer. In: Manni A (ed) Contemporary Endocrinology: Endocrinology of Breast Cancer. Vol 14, Humana Press, Totowa, NJ, 1998, pp 205-220
23. Kardas I, Seitz G, Limon J, Niezubitowski A, Rys J, Theisinger B, Welter C, Blin N: Retrospective analysis of prognostic significance of the estrogen- inducible pS2 gene in male breast carcinoma. Cancer 72: 1652-1656, 1993
24. Rogers S, Day CA, Fox SB: Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 24: 148-151, 1993
25. Bruce DM, Heys SD, Payne S, Miller ID, Eremin O: Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 22: 42-46, 1996
26. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333: 1444-1455, 1995
27. Foekens JA, Portengen H, van Putten WLJ, Peters HA, Krijnen HLLM, Alexieva-Figusch J, Klijn JGM: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49: 5823-5828, 1989
28. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontebal M, Janicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992
29. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Janicke F, Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994
30. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WLJ, Look MP, Klijn JGM, Kramer MD: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427, 1995
31. Grondahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappol H, Ronne E, Dano K, Klijn JGM, Brunner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995
32. Ronne E, Hoyer-Hansen G, Brunner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J: Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199-207, 1995
33. Foekens JA, van Putten WL, Portengen H, de Koning HY, Thirion B, Alexieva-Figusch J, Klijn JGM: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 11: 899-908, 1993
34. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J AM Stat Assoc 53: 457-481, 1958
35. Erlichman C, Murphy KC, Elhakim T: Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 2: 903-909, 1984
36. Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, Durand M, Dische S, Cleton FJ, Zewuster R, Fang Cui M, Lane W, Richter R: The prognosis of breast cancer in males. A report of 335 cases. Cancer 71: 154-161, 1993
37. Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, Resbeut M, Graic Y, Campana Fl Moncho-Bernier V, De Gislain C, Tortochaux J, Cuillere JC, Reme-Saumon M, N'Guyen TD, Lesaunier F, Le Simle T, Gamelin E, Hery M, Berlie J: Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A: 1960-1964, 1995
38. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85: 1206-1219, 1993
39. Yap HY, Tashima CK, Blumenschein GR, Eckles NE: Male breast cancer: a natural history study. Cancer 44: 748-754, 1979
40. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, O'Brien PC: A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 2: 325-333, 1993
41. Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53: 538-549, 1993
42. Vetto J, Jun SY, Padduch D, Eppich H, Shih R: Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 177: 379-383, 1999
43. Goss PE, Reid C, Pintilie M, Lim R, Miller N: Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85: 629-639, 1999
44. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA: Carcinoma of the male breast. Ann Intern Med 117: 771-777, 1992
45. Ribeiro G: Male breast carcinoma-a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 51: 115-119, 1985
46. Crichlow RW, Galt SW: Male breast cancer. Surg Clin North Am 70: 1165-1177, 1990
47. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71-85, 1992
48. Patel HZd, Buzdar AU, Hortohagyi GN: Role of adjuvant chemotherapy in male breast cancer. Cancer 64: 1583-1585, 1989
49. Ribeiro G, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65: 252-254, 1992
50. Wagner JL, Thomas CR, Jr., Koh WJ, Rudolph RH: Carcinoma of the male breast: update 1994. Med Pediatr Oncol 24: 123-132, 1995
51. Morimoto T, Komaki K, Yamakawa T, Tanaka T, Oomine Y, Konishi Y, Mori T, Monden Y: Cancer of the male breast. J Surg Oncol 44: 180-184, 1990
52. Stalsberg H, Thomas DB, Rosenblatt KA, Jimenez LM, McTiernan A, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF: Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control 4: 143-151, 1993
53. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH: Molecular markers in male breast carcinoma. Cancer 83: 1947-1955, 1998
54. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996
55. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997